The disulfide bonds of the nanocapsules can sense glutathione levels and release the Cas9 ribonucleoprotein/sgRNA complex in tumor cells with high glutathione concentrations.[48, 49] The hepatocellular cancer cell‐specific binding of the SP94 polypeptide on the surface of the nanocapsules facilitates specific tumor in vivo delivery.[25] Therefore, our nanocapsules could target liver cancer cells, release capsule content at the tumor site, and successfully knock out GDF15 genes. Here, GDF15 is linked to hepatocellular carcinoma.